Advanced Ovarian Cancer (DBCOND0037926)

Identifiers

Synonyms

Advanced-stage Ovarian Cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cisplatin	A platinum based chemotherapy agent used to treat various sarcomas, carcinomas, lymphomas, and germ cell tumors.	DNAtarget ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 5transporter ATP-binding cassette sub-family C member 2transporter Solute carrier family 22 member 2transporter High affinity copper uptake protein 1transporter Protein SLC31A2transporter ATP-binding cassette sub-family C member 6transporter Copper-transporting ATPase 2transporter Copper-transporting ATPase 1transporter Prostaglandin G/H synthase 2enzyme Myeloperoxidaseenzyme Xanthine dehydrogenase/oxidaseenzyme Arylamine N-acetyltransferaseenzyme Cytochrome P450 2C9enzyme Cytochrome P450 2B6enzyme Cholinesteraseenzyme Cytochrome P450 4A11enzyme Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Glutathione S-transferase theta-1enzyme Metallothionein-1Aenzyme Metallothionein-2enzyme Superoxide dismutase [Cu-Zn]enzyme Glutathione S-transferase Penzyme NAD(P)H dehydrogenase [quinone] 1enzyme Glutathione S-transferase Mu 1enzyme DNA-3-methyladenine glycosylasetarget Alpha-2-macroglobulintarget Albumincarrier Serotransferrintarget Copper transport protein ATOX1target
Doxorubicin	A medication used to treat various cancers, including AIDS-associated Kaposi's Sarcoma and metastatic cancers.	DNA topoisomerase 2-alphatarget DNAtarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2B6enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 6transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Bile salt export pumptransporter Solute carrier family 22 member 16transporter Mitochondrial potassium channel ATP-binding subunittransporter Cytochrome P450 1B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme Aldo-keto reductase family 1 member A1enzyme Aldo-keto reductase family 1 member C3enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Xanthine dehydrogenase/oxidaseenzyme Nitric oxide synthase 3enzyme Nitric oxide synthase, inducibleenzyme Nitric oxide synthase 1enzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme NADPH--cytochrome P450 reductaseenzyme RalA-binding protein 1transporter ATP-binding cassette sub-family C member 2transporter Albumincarrier Nucleolar and coiled-body phosphoprotein 1target DNA topoisomerase 1target DNA topoisomerase 2-betatarget Aldo-keto reductase family 1 member B1enzyme Aldo-keto reductase family 1 member B10enzyme Aldo-keto reductase family 1 member C4enzyme Telomerase reverse transcriptasetarget
Gemcitabine	A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.	Ribonucleoside-diphosphate reductase large subunittarget UMP-CMP kinasetarget Thymidylate synthasetarget Cytidine deaminaseenzyme Deoxycytidine kinaseenzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 10transporter Equilibrative nucleoside transporter 1transporter DNAtarget Sodium/nucleoside cotransporter 1transporter Equilibrative nucleoside transporter 2transporter Solute carrier family 28 member 3transporter Thymidine kinase 2, mitochondrialenzyme UMP-CMP kinaseenzyme Nucleoside diphosphate kinase Aenzyme Ribonucleoside-diphosphate reductase subunit M2target
Niraparib	A poly-ADP ribose polymerase inhibitor used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum based chemotherapy.	Poly [ADP-ribose] polymerase 1target Poly [ADP-ribose] polymerase 2target Carboxylesteraseenzyme Cytochrome P450 1A2enzyme Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter ATP-dependent translocase ABCB1transporter Albumincarrier
Olaparib	A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.	Poly [ADP-ribose] polymerase 1target Cytochrome P450 3A4enzyme Cytochrome P450 2B6enzyme Poly [ADP-ribose] polymerase 2target Protein mono-ADP-ribosyltransferase PARP3target Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Aldo-keto reductase family 1 member C3target UDP-glucuronosyltransferase 1A1enzyme Albumincarrier Alpha-1-acid glycoprotein 1carrier
Paclitaxel	A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 2C8enzyme Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Bile salt export pumptransporter ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Aromataseenzyme Cytochrome P450 1B1enzyme Solute carrier organic anion transporter family member 1B3transporter Nuclear receptor subfamily 1 group I member 2target Microtubule-associated protein 4target Microtubule-associated protein 2target Microtubule-associated protein tautarget ATP-binding cassette sub-family C member 2transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03491033	Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy	No drug interventions	Not Available	Not Available	completed
NCT06547840	A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer	No drug interventions	treatment	1	recruiting
NCT05775549	A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer	No drug interventions	Not Available	Not Available	completed
NCT03737643	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients	Bevacizumab Carboplatin Durvalumab Olaparib Paclitaxel	treatment	3	active_not_recruiting
NCT03611179	Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer	Bevacizumab	treatment	2	unknown_status
NCT01290471	Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors	No drug interventions	treatment	1	completed
NCT04065009	The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer	Ropivacaine	other	3	active_not_recruiting
NCT01462149	Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer	Carboplatin	treatment	2	completed
NCT06055348	SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer	Gemcitabine Paclitaxel	treatment	1 / 2	not_yet_recruiting
NCT04360629	Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer	Tranexamic acid	other	Not Available	completed
NCT03292172	A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer	Atezolizumab RO-6870810	treatment	1	terminated
NCT01989546	Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations	Talazoparib	treatment	1 / 2	completed
NCT04135521	Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer	No drug interventions	Not Available	Not Available	completed
NCT03161132	Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin	Doxorubicin Olaparib	treatment	2	completed
NCT05794659	Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer	Carboplatin Paclitaxel Sargramostim	treatment	2	not_yet_recruiting
NCT06542549	Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer	Cadonilimab	treatment	3	not_yet_recruiting
NCT03878849	Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®	2X-121	treatment	2	active_not_recruiting
NCT00516724	Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel	Carboplatin Olaparib Paclitaxel	treatment	1	completed
NCT03158935	The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial	Aldesleukin Cyclophosphamide Fludarabine	treatment	1	completed
NCT01844986	Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.	Olaparib	treatment	3	active_not_recruiting
NCT04556539	Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer	No drug interventions	treatment	2	unknown_status
NCT04862325	SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS	No drug interventions	prevention	Not Available	recruiting
NCT05924776	Plasmodium Immunotherapy for Advanced Ovarian Cancer	No drug interventions	treatment	2 / 3	not_yet_recruiting